“Data showing the impact of ifosfamide on improved overall survival for patients with recurrent and primary refractory Ewing sarcoma are potentially practice changing. Prior to this trial, no direct comparison of the most commonly available regimens were available to help guide treatment choices. Findings from the rEECur trial could help physicians talk with patients and their families about the likelihood of response, survival, and toxicity for each regimen available for relapsed Ewing sarcoma based on objective, randomized data,” said Vicki L. Keedy, MD, MSc, ASCO Expert in sarcoma.
CHICAGO — Use of high-dose ifosfamide (Ifex®) was found to be superior for treating recurrent and primary refractory Ewing sarcoma compared to three other standard-of-care treatments that are used for the disease, according to research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Study at a Glance
Which of four chemotherapy options is superior for treating recurrent and primary refractory Ewing sarcoma
451 patients in Europe with recurrent and primary refractory Ewing sarcoma
This is the first randomized trial to compare different chemotherapy regimens in recurrent and primary refractory Ewing sarcoma; previous studies were single arm trials or case series. Before this trial, it was not possible to say which regimen was most effective or most toxic.
The rEECur study, the first trial to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in recurrent and primary refractory Ewing sarcoma, showed that high-dose ifosfamide prolonged median event-free survival by 5.7 months compared to 3.7 months for topotecan plus cyclophosphamide. Median OS was 16.8 months for ifosfamide vs. 10.4 months for topotecan plus cyclophosphamide. A greater survival difference was observed for patients under age 14 than those 14 and older.
In earlier phases of the trial, irinotecan plus temolozomide and gemcitabine plus docetaxel were found to be inferior to ifosfamide and those enrollment arms were dropped from the trial. Ifosfamide led to more brain and kidney toxicity than topotecan plus cyclophosphamide. Both ifosfamide and topotecan plus cyclophosphamide led to similar febrile neutropenia (fever and a lower-than-normal number of neutrophils, a type of white blood cell) in 26% and 25% of patients, respectively. Quality-of-life scores favored ifosfamide over topotecan plus cyclophosphamide in children but not in adults.
“The rEECur study has, for the first time, accrued randomized data for four widely used chemotherapy regimens and is now accruing data for a fifth regimen. Before the rEECur study, the basis for choosing drugs for patients with relapsed or refractory Ewing sarcoma was weak and lacking randomized trials to inform clinicians or patients about which treatments were most effective and/or most toxic,” said lead author Martin McCabe, MD, PhD, who is a clinical senior lecturer in pediatric and adolescent oncology at the University of Manchester, England.
Ifosfamide, first approved for use in the United States (U.S.) in 1987, works by adding an alkyl group to DNA, leading to an eventual breaking of DNA strands and affecting the ability of cancer cells to multiply.
The current five-year survival rate of recurrent and primary refractory Ewing sarcoma is about 15%. Ewing tumors are uncommon as only about 200 children and teens are diagnosed with the disease in the U.S. each yeari.
About the Study
The phase II/III rEECur trial randomly assigned patients in Europe, ages 4 to 50 (median age of 19) with recurrent and primary refractory Ewing sarcoma to either topotecan plus cyclophosphamide, irinotecan plus temolozomide, gemcitabine plus docetaxel, or high-dose ifosfamide. The primary outcome was event-free survival in the phase III comparison. Secondary outcomes included reviews of responses by imaging, OS, toxicity, and quality of life. At the first and second interim assessments, patients receiving irinotecan plus temolozomide and gemcitabine plus docetaxel had worse objective responses and event-free survival than the other treatments, thereby halting recruitment to both groups. The final assessment was a phase III evaluation of topotecan plus cyclophosphamide vs. ifosfamide. Median follow-up was 40 months.
The regimens were chosen because they were the most widely used regimens for recurrent/refractory Ewing sarcoma in Europe at the time the trial was established. These choices were important as some regimens, notably irinotecan plus temolozomide and topotecan plus cyclophosphamide, were being used as the chemotherapy backbone in trials with molecularly targeted agents.
The trial is continuing to recruit patients to the ifosfamide arm. It has also added a fifth chemotherapy arm that includes carboplatin and an etoposide, an agent which can damage DNA. The investigators plan to introduce a new arm involving a molecularly targeted therapeutic later this year.
The rEECur trial was funded by the Cancer Research UK and European Commission with additional funding from the Aamu Pediatric Cancer Foundation, Australia and New Zealand Children's Hematology and Oncology Group, Australia and New Zealand Sarcoma Association, Canteen, German Cancer Aid, Swiss Pediatric Oncology Group and the Zoé4life 4life Other Foundation.
View the full embargoed abstract
View the disclosures for ASCO’s Cancer Communications Committee: https://www.asco.org/sites/new-www.asco.org/files/content-files/about-asco/pdf/2022-asco-ccc-disclosures.pdf
For your readers:
- Guide to Ewing Sarcoma – Childhood and Adolescence
- Understanding Chemotherapy
- Dealing with Cancer Recurrence
ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.
[i] Survival rates for Ewings Tumors: The American Cancer Society: https://www.cancer.org/cancer/ewing-tumor/detection-diagnosis-staging/survival-rates.html
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.